Outlook Therapeutics Regains Nasdaq Compliance but Flags Persistent Delisting Risk Ahead of July 16 Vote
OTLK has more than doubled off its 52-week low of $0.161.
Summary
Outlook Therapeutics regained Nasdaq compliance after its stock held above $1.00 for ten days, but warns that the price remains near the threshold and could fall again, risking delisting. The supplement updates the proxy for the July 16 special meeting where shareholders vote on a reverse stock split and share authorization increase.
Key Events · Legal and Risk Events · OTLK
-
Nasdaq Delisting Matter Closed
Nasdaq notified the company on June 26, 2026 that it regained compliance with the minimum bid price rule after the stock closed at or above $1.00 for ten consecutive business days (June 11-25, 2026). The delisting matter is now closed.
-
Ongoing Delisting Risk Highlighted
Despite regaining compliance, the company warns that the stock price was only $1.68 as of July 9, 2026, and any adverse developments could cause it to fall below $1.00 again, potentially triggering new delisting proceedings.
-
Reverse Stock Split Remains Critical
The board emphasizes that if the stock price falls below $1.00 again, the approved reverse stock split (Proposal 3 at the July 16 special meeting) would be a key tool to regain compliance, but it must be implemented within one year of stockholder approval.
-
Proxy Supplement Ahead of July 16 Vote
This DEFA14A supplements the definitive proxy statement filed June 1, 2026, updating stockholders on Nasdaq compliance status and reinforcing the need for the reverse stock split and share authorization proposals.
Analysis · OTLK · Life Sciences
Outlook Therapeutics disclosed that Nasdaq closed its delisting matter after the stock held above $1.00 for ten consecutive days through June 25, 2026. Yet the company cautions that the stock price was only $1.68 as of July 9, 2026, and any adverse developments could push it back below $1.00, triggering new delisting proceedings. This supplement to the proxy statement for the July 16 special meeting underscores the fragility of the company's Nasdaq listing even as it seeks shareholder approval for a reverse stock split and massive dilution. The going concern warning and recent dilutive financings amplify the risk that the stock could again fall below the threshold, making the reverse split proposal a critical safeguard.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 37.4% of the 3413 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OTLK was trading at $1.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $269M. The 52-week trading range was $0.16 to $3.39. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.